Clinical Trials Browser

Phase 2 × Recruiting × quizartinib × Clear all

NCT06824168 2025-12-04

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute